For now, surgery is the gold standard for the treatment of localized primary GIST without metastasis [8], and imatinib mesylate (IM), which is a receptor tyrosine kinase inhibitor, is reportedly effective in patients with metastatic GIST, and adjuvant imatinib treatment improves GIST prognosis dramatically [9, 10]. The gene discussed is NTRK1; the disease is gastrointestinal stromal tumor.